Q3 Revenue Decline and EPS Guidance Cut Signal Slower Turnaround

What happened

Dentsply Sirona reported Q3 2026 net sales of $836 million, a decline from Q2's $898 million, and updated FY2026 guidance to approximately $3.5 billion in revenue and adjusted EPS of $1.20–$1.30, down from the prior range of $1.40–$1.50. The company posted a GAAP diluted loss of ($0.01) per share, but adjusted EPS of $0.29 and adjusted EBITDA margin of 17.3% remained weak relative to the implied pre-2025 profitability. Management highlighted record Wellspect Healthcare quarterly sales with 10.1% as-reported growth and the completed U.S. Surity urinary management portfolio, yet these bright spots failed to offset continued softness in dental segments, as evidenced by the lowered outlook. The distributor expansion initiatives, including Atlanta Dental Supply and Medline Sinclair, have not yet delivered the anticipated CTS revenue lift, and the guidance cut suggests EMEA destocking and digital pricing pressure persist. Overall, the Q3 print confirms that the turnaround remains ahead of the income statement, with restructuring savings still not visible in organic margin improvement after adjusting for one-time items.

Implication

We maintain a WAIT rating but note that the thesis has weakened as management's reduced guidance signals a slower path to stabilization. The updated outlook implies Q4 revenue of roughly $886 million, which would still show year-over-year decline, and adjusted EPS guidance of $1.20–$1.30 suggests continued margin pressure from pricing and mix. While Wellspect provides a reliable growth pocket and restructuring savings may eventually materialize, the lack of CTS improvement after two quarters of distributor expansion is concerning. The balance sheet remains leveraged with net debt of $2.14 billion and interest coverage near 4.7, limiting flexibility if cash flow weakens further. Investors should wait for evidence of positive constant-currency growth in CTS and a non-adjusted gross margin above 55% before considering entry; otherwise, the bear case of low digital pricing and persistent EMEA weakness may drive the stock toward the $9.00 implied value.

Thesis delta

The original thesis anticipated Q3 2026 as a pivotal checkpoint for distributor expansion and gross margin quality; the actual results show revenue contraction and a substantial EPS guidance cut, indicating the recovery is delayed. Consequently, the probability of the base case (implied value $12.50) has declined, while the bear case (implied value $9.00) has become more probable given continued negative segment trends. The WAIT rating remains appropriate, but the attractive entry level of $10.00 now appears less compelling unless Q4 shows a clear inflection in CTS constant-currency growth and organic margin improvement.